These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 26232760)

  • 21. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
    West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
    mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model.
    Li W; Yang W; Liu X; Zhou W; Wang S; Wang Z; Zhao Y; Feng N; Wang T; Wu M; Ge L; Xia X; Yan F
    Emerg Microbes Infect; 2024 Dec; 13(1):2392651. PubMed ID: 39155772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
    Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.
    Banadyga L; Zhu W; Kailasan S; Howell KA; Franaszek K; He S; Siragam V; Cheng K; Yan F; Moffat E; Cao W; Leung A; Embury-Hyatt C; Aman MJ; Qiu X
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
    Howell KA; Brannan JM; Bryan C; McNeal A; Davidson E; Turner HL; Vu H; Shulenin S; He S; Kuehne A; Herbert AS; Qiu X; Doranz BJ; Holtsberg FW; Ward AB; Dye JM; Aman MJ
    Cell Rep; 2017 Apr; 19(2):413-424. PubMed ID: 28402862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection.
    Shcheblyakov D; Esmagambetov I; Simakin P; Kostina L; Kozlov A; Tsibezov V; Grebennikova T; Chifanov D; Rumyantseva I; Boyarskaya N; Sizikova T; Shagarova N; Andrus А; Shatohina I; Syromyatnikova S; Kovalchuk A; Pantyukhov V; Borisevich S; Zubkova O; Tukhvatulin A; Logunov D; Naroditsky B; Gintsburg A
    Antiviral Res; 2019 Dec; 172():104617. PubMed ID: 31593751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.
    Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR
    J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
    Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
    Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shedding of Ebola Virus Surface Glycoprotein Is a Mechanism of Self-regulation of Cellular Cytotoxicity and Has a Direct Effect on Virus Infectivity.
    Dolnik O; Volchkova VA; Escudero-Perez B; Lawrence P; Klenk HD; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S322-8. PubMed ID: 26092855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.
    Konduru K; Shurtleff AC; Bavari S; Kaplan G
    J Virol Methods; 2018 Apr; 254():1-7. PubMed ID: 29355585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry.
    Hoffmann M; Crone L; Dietzel E; Paijo J; González-Hernández M; Nehlmeier I; Kalinke U; Becker S; Pöhlmann S
    J Virol; 2017 May; 91(9):. PubMed ID: 28228590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    Maruyama T; Rodriguez LL; Jahrling PB; Sanchez A; Khan AS; Nichol ST; Peters CJ; Parren PW; Burton DR
    J Virol; 1999 Jul; 73(7):6024-30. PubMed ID: 10364354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
    Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
    Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.
    Ilinykh PA; Shen X; Flyak AI; Kuzmina N; Ksiazek TG; Crowe JE; Bukreyev A
    J Virol; 2016 Apr; 90(8):3890-3901. PubMed ID: 26819310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
    J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.